Analyst consensus rating

Protara Therapeutics Analyst Rating: Strong Buy

Direct answer

Protara Therapeutics's consensus rating is Strong Buy.

6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.33.
Forecast evidence checked November 21, 2026.

Get free Protara Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$2.28
Average price target
$25.33
High price target
$30.00
Low price target
$18.00
Low target gap
+689.5%
Target upside
+1,011.1%
High target gap
+1,215.8%
Target range width
526.3%
Consensus rating
Strong Buy
Analysts
6
Evidence date
November 21, 2026
Valid through
November 28, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Protara Therapeutics?

Protara Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $25.33.

How far are Protara Therapeutics's low and high targets from the recorded price?

The low target implies +689.5%, while the high target implies +1,215.8%.

How many analysts are included in Protara Therapeutics's consensus?

The verified consensus includes 6 analysts.

How is Protara Therapeutics's target upside or downside calculated?

The average target of $25.33 is divided by the recorded price of $2.28, then one is subtracted to produce +1,011.1%. This does not guarantee a future return.

When was Protara Therapeutics's analyst forecast verified?

The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.